FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or S	ection	1 30(h) o	of the	Investment	Con	npany Act	ot 1940								
1. Name and Address of Reporting Person* Singh Shawn						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Excaliber Enterprises, Ltd. [ EXCA ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) 384 OYSTER POINT BLVD., NO. 8					3. Date of Earliest Transaction (Month/Day/Year) 05/11/2011									- X	below)	give title	Other (specify below)			
(Street) SOUTH SAN FRANCISCO CA 94080					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip)																				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					ction	2A Ex r) if a	2A. Deemed Execution Date, if any (Month/Day/Year		3. Transaction Code (Instr.		osed of, or Benefic 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			) or	5. Amoun	s Illy	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
										v	Amount	(A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 05/11					1/2011		A		76,08	6,087 A		\$3.5 <sup>(1)</sup>	76,087				By Trust <sup>(2)</sup>			
			Table II -						uired, Di						Owned					
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date curity or Exercise (Month/Day/Year)		3A. Deemed Execution Da if any (Month/Day/)	ned 4. n Date, Trar Cod		5. Don Do cr. So Oi	5. Number of Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		able and			ount	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	de V	(A			Date Exercisable		xpiration ate	Title	or Nu	ount nber Shares	Transacti (Instr. 4)					
Stock Option (Right to Buy)	\$4.2	05/11/2011		A	1	1	10,000		(3)	0	1/17/2018	Commo		),000	(4)	10,00	0	D		
Stock Option (Right to Buy)	\$4.2	05/11/2011		A		1	10,000		(3)	0	1/17/2018	Commo		),000	(4)	10,00	0	D		
Stock Option (Right to Buy)	\$2.26	05/11/2011		A		3	30,000		(5)	0	3/24/2019	Commo Stock	<sup>n</sup> 30	),000	(6)	30,00	0	D		
Stock Option (Right to Buy)	\$2.26	05/11/2011		A		1	11,250		(7)	0	6/17/2019	Commo Stock		.,250	(8)	11,25	0	D		
Stock Option (Right to Buy)	\$3	05/11/2011		A		50	00,000		(9)	1	1/04/2019	Commo		0,000	(10)	500,00	00	D		
Stock Option (Right to Buy)	\$3	05/11/2011		A		21	12,500		(11)	1	2/30/2019	Commo Stock		2,500	(12)	212,50	00	D		
Stock Option (Right to Buy)	\$3.5	05/11/2011		A		5	50,000		(13)	0	4/26/2021	Commo Stock		),000	(14)	50,00	0	D		
Warrant	\$3.5	05/11/2011		A			750		07/28/2006	1	2/31/2013	Commo		750	(15)	750		D		
Stock Option (Right to Buy)	\$1.6	05/11/2011		A		1	10,000		12/21/2007	1	2/21/2016	Commo Stock		),000	(16)	10,00	0	I	By Trust <sup>(2)</sup>	
Stock Option (Right to Buy)	\$1.44	05/11/2011		A		2	20,000		01/01/2009	0	5/17/2017	Commo Stock		),000	(17)	20,00	0	I	By Trust <sup>(2)</sup>	
Warrant	\$3.5	05/11/2011		A		4	10,169		08/25/2008	1	2/31/2013	Commo	n 40	),169	(18)	40,16	9	I	By Trust <sup>(2)</sup>	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrant	\$3.5	05/11/2011		A		17,857		08/25/2008	12/31/2013	Common Stock	17,857	(19)	17,857	I	By Trust <sup>(2</sup>

## **Explanation of Responses:**

- 1. Shares received in a stock-for-stock exchange of shares of VistaGen Therapeutics Inc. ("VistaGen") Common Stock in connection with the Agreement and Plan of Merger by and among VistaGen, the Issuer and a wholly-owned subsidiary of Issuer, such that VistaGen became a wholly-owned subsidiary of Issuer (the "Merger"). The exchange ratio in connection with the Merger was one share of VistaGen Common Stock at a price of \$1.75 per share for 0.5 shares of Issuer Common Stock at a price of \$3.50 per share (the "Exchange Ratio"). All shares reflected in the Tables and the footnotes give effect to the Exchange Ratio.
- 2. Held by The 1997 Singh Family Trust U/R/D 5/29/97.
- 3. Options vest monthly over a period of four years commencing January 17, 2008, with a twelve-month cliff of 25% of the shares.
- 4. Received in the Merger in exchange for an employee stock option to acquire 10,000 shares of VistaGen common stock for \$4.20 per share.
- 5. Options vest monthly over a period of four years commencing March 24, 2009, with a twelve-month cliff of 25% of the shares.
- 6. Received in the Merger in exchange for an employee stock option to acquire 30,000 shares of VistaGen common stock for \$2.26 per share.
- 7. Options yest 50% after three months and 50% after six months commencing June 17, 2009.
- 8. Received in the Merger in exchange for an employee stock option to acquire 11,250 shares of VistaGen common stock for \$2.26 per share.
- 9. Options vest monthly over a period of two years commencing January 17, 2008, with a twelve-month cliff of 50% of the shares.
- 10. Received in the Merger in exchange for an employee stock option to acquire 500,000 shares of VistaGen common stock for \$3.00 per share.
- 11. Options vest monthly over a period of three years commencing December 31, 2009, with a twelve-month cliff of 50% of shares.
- 12. Received in the Merger in exchange for an employee stock option to acquire 212, 500 shares of VistaGen common stock for \$3.00 per share.
- 13. Options vest monthly over a period of four years commencing April 25, 2011, with a twelve-month cliff of 25% of the shares.
- 14. Received in the Merger in exchange for an employee stock option to acquire 50,000 shares of VistaGen common stock for \$3.50 per share.
- $15. \ Received in the \ Merger in exchange for a warrant to acquire \ 750 \ shares of \ VistaGen \ common \ stock for \ \$3.50 \ per \ share.$
- 16. Received in the Merger in exchange for an employee stock option to acquire 10,000 shares of VistaGen common stock for \$1.60 per share.
- 17. Received in the Merger in exchange for an employee stock option to acquire 20,000 shares of VistaGen common stock for \$1.44 per share.
- 18. Received in the Merger in exchange for a warrant to acquire 40,169 shares of VistaGen common stock for \$3.50 per share.

  19. Received in the Merger in exchange for a warrant to acquire 17,857 shares of VistaGen common stock for \$3.50 per share.

<u>/s/ Shawn K. Singh</u> <u>05/25/2011</u>

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.